Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Indacaterol - Novartis

Drug Profile

Indacaterol - Novartis

Alternative Names: Arcapta Neohaler; Hirobriz Breezhaler; Indacaterol maleate; Onbrez Breezhaler; Onbrez Inhalation Capsules; Onbrize Breezhaler; Oslif Breezhaler; QAB 149

Latest Information Update: 01 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Antiasthmatics; Bronchodilators; Indans; Quinolones; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • Phase III Asthma

Most Recent Events

  • 17 Jul 2019 Novartis Pharmaceuticals completes a Phase II trial in Asthma (In children) in Belgium, Colombia, Croatia, Germany, Guatemala, Hungary, Philippines, Russia, Slovakia, South Africa and Turkey (NCT02892019)
  • 24 Jun 2019 Indacaterol inhalation licensed to Glenmark in Brazil
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top